Clinical Trials

MyeloidOther hematologic neoplasm

2,000 enrolled

Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myeloid, Acute

NCT05812807 2026-06-05

Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab

1,295 enrolled

Breast

Anatomic Stage II Breast Cancer AJCC v8

NCT06317649 2026-06-05

Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)

Other hematologic neoplasm

147 enrolled

Leukemia, Myeloid, Acute

NCT06447987 2026-06-05

Humanized CD19-Specific CAR T Cells for the Treatment of Patients With Positive Relapsed or Refractory CD19 Positive B-Cell Acute Lymphoblastic Leukemia

Phase 1 Suspended

24 enrolled

LymphoidOther hematologic neoplasm

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT06499870 2026-06-05

Relugolix and Enzalutamide in Combination With Radiation Therapy for the Treatment of Very High Risk Prostate Cancer, OPTIMAL Trial

50 enrolled

Prostate Adenocarcinoma

NCT07278856 2026-06-05

Ruxolitinib in Combination With CHOP Chemotherapy for the Treatment of Untreated Nodal T-Follicular Helper Cell Lymphomas

Phase 1 Recruiting

20 enrolled

Lymphoma, T-Cell

NCT07416188 2026-06-05

Novel Indenoisoquinolone CMYC/TOPOISOMERASE 1 Inhibitor (LMP744) in Recurrent Glioblastoma

40 enrolled

CNS

Brain Neoplasms, Glioblastoma, Glioma, Neoplasms, Neoplasms by Histologic Type, Neoplasms, Nerve Tissue, Recurrence, Central Nervous System Neoplasms

NCT07510334 2026-06-05

VSV-IFNβ-NIS With Ipilimumab and Nivolumab for the Treatment of Advanced or Metastatic Clear Cell Renal Cell Carcinoma

18 enrolled

Clear-cell metastatic renal cell carcinoma, Carcinoma, Renal Cell

NCT05521698 2026-06-04

A Randomized Trial of Bicalutamide in Non-Muscle Invasive Bladder Cancer

Phase 1 Recruiting

80 enrolled

Non-Muscle Invasive Bladder Urothelial Carcinoma

NCT05741164 2026-06-04

Propranolol and Pembrolizumab for Tumor Re-sensitization and Treatment of Patients With Checkpoint Inhibitor Refractory Metastatic or Unresectable Triple Negative Breast Cancer

37 enrolled

Breast

Triple Negative Breast Neoplasms

NCT06536049 2026-06-04

Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma

38 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT06948786 2026-06-04

Pirtobrutinib and Mosunetuzumab for the Treatment of Relapsed/Refractory Grades 1-3A Follicular Lymphoma, PROMOTE-FL Trial

22 enrolled

Phase 1 Not yet recruiting

Lymphoma, Follicular

NCT07062003 2026-06-04

MBRT1

Phase NA Recruiting

60 enrolled

DermatologicSarcoma

Sarcoma, Skin Neoplasms, Soft Tissue Neoplasms

NCT07619313 2026-06-04

AB801 in Combination With Chemotherapy and Immunotherapy for the Treatment of Patients With Borderline Resectable, Locally Advanced or Metastatic Cholangiocarcinoma or Pancreatic Cancer

46 enrolled

Pancreatic Neoplasms, Cholangiocarcinoma

NCT01810913 2026-06-03

Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer

Phase 2/3 Recruiting

613 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT02465060 2026-06-03

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

BreastCNSDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidOther hematologic neoplasmPlasma cellThoracic

6,452 enrolled 1 FDA

Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Glioma, Carcinoma, Hepatocellular, Lung Neoplasms, Lymphoma, Melanoma, Multiple Myeloma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Rectal Neoplasms, Stomach Neoplasms, Thyroid Neoplasms, Uterine Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Hematologic Neoplasms

NCT03739814 2026-06-03

Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia

84 enrolled

Burkitt Lymphoma

NCT04628767 2026-06-03

Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer

Phase 2/3 Recruiting

131 enrolled

Renal Pelvis and Ureter Urothelial Carcinoma

NCT04981509 2026-06-03

Testing of Bevacizumab, Erlotinib, and Atezolizumab in Combination for Advanced-Stage Kidney Cancer

65 enrolled

Hereditary leiomyomatosis and renal cell cancer, Papillary renal cell carcinoma, sporadic, Carcinoma, Renal Cell

NCT05554328 2026-06-03

Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Treatment Trial

165 enrolled

Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms

NCT06064097 2026-06-03

A Study Using Nivolumab, in Combination With Chemotherapy Drugs to Treat Nasopharyngeal Carcinoma (NPC)

50 enrolled

Head & Neck

Nasopharyngeal Carcinoma

NCT06102902 2026-06-03

Testing the Addition of Anti-cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment, Cetuximab Plus Encorafenib, for Colorectal Cancer

Phase 1 Suspended

30 enrolled

Colorectal Neoplasms

NCT06124157 2026-06-03

A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)

222 enrolled

Burkitt Lymphoma

NCT06130826 2026-06-03

Immune Response Activation for the Treatment of Unresectable Metastatic Colorectal Cancer or CEA Positive Metastatic Breast Cancer

Phase 1 Suspended

24 enrolled

BreastGastrointestinal

Breast Neoplasms, Colorectal Neoplasms

NCT06172296 2026-06-03

Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma

478 enrolled

CNS

Neuroblastoma, Ganglioneuroblastoma

NCT06325683 2026-06-03

Anti-Lag-3 (Relatlimab) and Anti-PD-1 Blockade (Nivolumab) Versus Standard of Care (Lomustine) for the Treatment of Patients With Recurrent Glioblastoma

Phase 2 Suspended

184 enrolled

CNS

Glioblastoma

NCT06696768 2026-06-03

Clinical Trial of an Anti-cancer Drug, CA-4948 (Emavusertib), in Combination With Chemotherapy Treatment (FOLFOX Plus Bevacizumab) in Metastatic Colorectal Cancer

Phase 1 Recruiting

24 enrolled

Colorectal Neoplasms

NCT06965114 2026-06-03

Testing the Combination of Anti-cancer Drugs, Tovorafenib Plus Rituximab, in Patients With Hairy Cell Leukemia

Other hematologic neoplasm

84 enrolled

Leukemia, Hairy Cell

NCT01585805 2026-06-02

Gemcitabine Hydrochloride and Cisplatin With or Without Veliparib or Veliparib Alone in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer

83 enrolled 23 charts

Pancreatic Neoplasms

NCT03150693 2026-06-02

Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia

310 enrolled

Burkitt Lymphoma

NCT03213704 2026-06-02

Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial)

CNSGastrointestinalGenitourinaryLymphoidMyeloidSarcoma

9 enrolled 12 charts

Ependymoma, Glioma, Histiocytosis, Langerhans-Cell, Lymphoma, Non-Hodgkin, Medulloblastoma, Wilms Tumor, Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Osteosarcoma, Central Nervous System Neoplasms, Hepatoblastoma, Neuroectodermal Tumors, Primitive, Peripheral, Rhabdoid Tumor

NCT03367741 2026-06-02

Cabozantinib S-malate and Nivolumab in Treating Patients With Advanced, Recurrent, or Metastatic Endometrial Cancer

82 enrolled 11 charts

GynecologicSarcoma

Carcinosarcoma, Endometrial Neoplasms

NCT03660826 2026-06-02

Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib Alone

288 enrolled 21 charts

Sarcoma

Carcinosarcoma, Carcinoma, Endometrioid

NCT04172532 2026-06-02

Testing the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiotherapy in Patients With Locally Advanced Pancreatic Cancer

92 enrolled

Pancreatic Neoplasms

NCT04458922 2026-06-02

Testing Atezolizumab in People 2-17 Years Old With Clear Cell Sarcoma or Advanced Chondrosarcoma

Phase 1 Active not recruiting

27 enrolled 16 charts

LymphoidSarcoma

Lymphoma, Follicular, Sarcoma, Clear Cell

NCT04514497 2026-06-02

Testing the Addition of an Anti-cancer Drug, BAY 1895344, to Usual Chemotherapy for Advanced Stage Solid Tumors, With a Specific Focus on Patients With Small Cell Lung Cancer, Poorly Differentiated Neuroendocrine Cancer, and Pancreatic Cancer

29 enrolled 25 charts

EndocrineGastrointestinalThoracic

Lung Neoplasms, Neoplasm Metastasis, Pancreatic Neoplasms, Carcinoma, Neuroendocrine, Small Cell Lung Carcinoma

NCT05564377 2026-06-02

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

2,900 enrolled

Gynecologic

Fallopian Tube Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Endometrial Neoplasms

NCT06126276 2026-06-02

Testing the Use of Neratinib or the Combination of Neratinib and Palbociclib Targeted Treatment for HER2+ Solid Tumors (A ComboMATCH Treatment Trial)

70 enrolled

Other solid neoplasm

Malignant Female Reproductive System Neoplasm

NCT06661720 2026-06-02

STRIKE

1,040 enrolled

Carcinoma, Renal Cell

NCT06672146 2026-06-02

Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)

Other hematologic neoplasm

93 enrolled

Leukemia, Myeloid, Acute

NCT07293403 2026-06-02

Duvelisib Maintenance for the Treatment of Peripheral T-Cell Lymphomas

25 enrolled

Phase EARLY_PHASE1 Active not recruiting

Lymphoma, T-Cell

NCT02210117 2026-06-01

Nivolumab With or Without Bevacizumab or Ipilimumab Before Surgery in Treating Patients With Metastatic Kidney Cancer That Can Be Removed by Surgery

104 enrolled

Carcinoma, Renal Cell

NCT03155620 2026-06-01

Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)